Renovorx files new international patent for novel targeted combination drug-delivery oncology therapy platform

Los altos, calif.--(business wire)--renovorx, inc. (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the company has filed an international patent application under the patent cooperation treaty (pct) for its novel trans-arterial micro-perfusion (tamp) therapy platform. the company already holds a strong intellectual property portfolio with 9 issued patents and 9 pending patents.
RNXT Ratings Summary
RNXT Quant Ranking